Cargando…

Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study

Most people with cystic fibrosis (pwCF) develop pancreatic insufficiency and are treated with pancreatic enzyme replacement therapy (PERT). We aimed to describe the use of PERT and assess the correlates of PERT dose in adult pwCF. In a cross-sectional study at the Copenhagen CF Centre, the participa...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsen, Mette F., Kjøller-Svarre, Maria S., Møller, Grith, Katzenstein, Terese L., Nielsen, Bibi U., Pressler, Tacjana, Lewis, Jack I., Mathiesen, Inger H., Mølgaard, Christian, Faurholt-Jepsen, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003007/
https://www.ncbi.nlm.nih.gov/pubmed/35405943
http://dx.doi.org/10.3390/nu14071330
_version_ 1784686027987746816
author Olsen, Mette F.
Kjøller-Svarre, Maria S.
Møller, Grith
Katzenstein, Terese L.
Nielsen, Bibi U.
Pressler, Tacjana
Lewis, Jack I.
Mathiesen, Inger H.
Mølgaard, Christian
Faurholt-Jepsen, Daniel
author_facet Olsen, Mette F.
Kjøller-Svarre, Maria S.
Møller, Grith
Katzenstein, Terese L.
Nielsen, Bibi U.
Pressler, Tacjana
Lewis, Jack I.
Mathiesen, Inger H.
Mølgaard, Christian
Faurholt-Jepsen, Daniel
author_sort Olsen, Mette F.
collection PubMed
description Most people with cystic fibrosis (pwCF) develop pancreatic insufficiency and are treated with pancreatic enzyme replacement therapy (PERT). We aimed to describe the use of PERT and assess the correlates of PERT dose in adult pwCF. In a cross-sectional study at the Copenhagen CF Centre, the participants reported PERT intake, gastrointestinal (GI) symptoms and the use of concomitant treatments. Demographic and clinical characteristics were extracted from the Danish CF Registry. We used linear regression to assess the correlates of PERT dose per kg bodyweight (U-lipase/kg). We included 120 pwCF with a median age of 32.9 years, 46% women and 72% F508delta homozygote. The PERT dose ranged from 0 to 6160 U-lipase/kg per main meal (mean 1828; SD 1115). The PERT dose was associated with participants’ sex (men vs. women: 661; 95% CI: 302; 1020 U-lipase/kg), age (−16; 95% CI: −31; −1 U-lipase/kg per year) and weight (−45; 95% CI: −58; −31 U-lipase/kg per kg). Having less frequent constipation and being lung transplanted were also associated with a higher PERT dose. A third of participants did not take PERT for snacks, and this was associated with the frequency of diarrhoea. These findings indicate that PERT intake may be improved to reduce GI symptoms.
format Online
Article
Text
id pubmed-9003007
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90030072022-04-13 Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study Olsen, Mette F. Kjøller-Svarre, Maria S. Møller, Grith Katzenstein, Terese L. Nielsen, Bibi U. Pressler, Tacjana Lewis, Jack I. Mathiesen, Inger H. Mølgaard, Christian Faurholt-Jepsen, Daniel Nutrients Article Most people with cystic fibrosis (pwCF) develop pancreatic insufficiency and are treated with pancreatic enzyme replacement therapy (PERT). We aimed to describe the use of PERT and assess the correlates of PERT dose in adult pwCF. In a cross-sectional study at the Copenhagen CF Centre, the participants reported PERT intake, gastrointestinal (GI) symptoms and the use of concomitant treatments. Demographic and clinical characteristics were extracted from the Danish CF Registry. We used linear regression to assess the correlates of PERT dose per kg bodyweight (U-lipase/kg). We included 120 pwCF with a median age of 32.9 years, 46% women and 72% F508delta homozygote. The PERT dose ranged from 0 to 6160 U-lipase/kg per main meal (mean 1828; SD 1115). The PERT dose was associated with participants’ sex (men vs. women: 661; 95% CI: 302; 1020 U-lipase/kg), age (−16; 95% CI: −31; −1 U-lipase/kg per year) and weight (−45; 95% CI: −58; −31 U-lipase/kg per kg). Having less frequent constipation and being lung transplanted were also associated with a higher PERT dose. A third of participants did not take PERT for snacks, and this was associated with the frequency of diarrhoea. These findings indicate that PERT intake may be improved to reduce GI symptoms. MDPI 2022-03-22 /pmc/articles/PMC9003007/ /pubmed/35405943 http://dx.doi.org/10.3390/nu14071330 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Olsen, Mette F.
Kjøller-Svarre, Maria S.
Møller, Grith
Katzenstein, Terese L.
Nielsen, Bibi U.
Pressler, Tacjana
Lewis, Jack I.
Mathiesen, Inger H.
Mølgaard, Christian
Faurholt-Jepsen, Daniel
Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study
title Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study
title_full Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study
title_fullStr Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study
title_full_unstemmed Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study
title_short Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study
title_sort correlates of pancreatic enzyme replacement therapy intake in adults with cystic fibrosis: results of a cross-sectional study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003007/
https://www.ncbi.nlm.nih.gov/pubmed/35405943
http://dx.doi.org/10.3390/nu14071330
work_keys_str_mv AT olsenmettef correlatesofpancreaticenzymereplacementtherapyintakeinadultswithcysticfibrosisresultsofacrosssectionalstudy
AT kjøllersvarremarias correlatesofpancreaticenzymereplacementtherapyintakeinadultswithcysticfibrosisresultsofacrosssectionalstudy
AT møllergrith correlatesofpancreaticenzymereplacementtherapyintakeinadultswithcysticfibrosisresultsofacrosssectionalstudy
AT katzensteinteresel correlatesofpancreaticenzymereplacementtherapyintakeinadultswithcysticfibrosisresultsofacrosssectionalstudy
AT nielsenbibiu correlatesofpancreaticenzymereplacementtherapyintakeinadultswithcysticfibrosisresultsofacrosssectionalstudy
AT presslertacjana correlatesofpancreaticenzymereplacementtherapyintakeinadultswithcysticfibrosisresultsofacrosssectionalstudy
AT lewisjacki correlatesofpancreaticenzymereplacementtherapyintakeinadultswithcysticfibrosisresultsofacrosssectionalstudy
AT mathieseningerh correlatesofpancreaticenzymereplacementtherapyintakeinadultswithcysticfibrosisresultsofacrosssectionalstudy
AT mølgaardchristian correlatesofpancreaticenzymereplacementtherapyintakeinadultswithcysticfibrosisresultsofacrosssectionalstudy
AT faurholtjepsendaniel correlatesofpancreaticenzymereplacementtherapyintakeinadultswithcysticfibrosisresultsofacrosssectionalstudy